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A novel chromogenic medium CHROMagarmSuperCARBAwas evaluated to detect carbapenem-resistant Gram-
negatives. This medium is as sensitive and as speciﬁc as the SUPERCARBA medium for detecting KPC, MBL and
OXA-48-type producers (100% and 100%, respectively) and is compatible with subsequent testing of
carbapenemase activity using the RAPIDEC® CARBA NP.
Carbapenemase-producing Enterobacteriaceae (CPE) are increas-
ingly reported worldwide (Pitout and Laupland, 2008). Mortality rates
as high as 69% due to infections caused by these bacteria have been
reported (Djahmi et al., 2014). Carbapenem resistance in Entero-
bacteriaceae has become worrisome since the spread of KPC-type
carbapenemases among Klebsiella pneumoniae isolates in the 2000’s
(Yigit et al., 2001). Worldwide spread of carbapenemase producers
has been facilitated by the mobilization of carbapenemase genes from
mobile genetic elements (conjugative plasmids, integrons or transpo-
sons) among different enterobacterial species (Nordmann and Poirel,
2014). In this context, the rapid detection of these microorganisms is
critical for preventing the development of nosocomial outbreaks.
The main groups of carbapenemases identiﬁed in Enterobacteriace-
ae are Ambler class A (KPC-type) that are able to hydrolyze allβ-lactams
except cephamycins, the zinc-dependent metallo-β-lactamases (MBL)
Ambler class B (NDM, VIM, and IMP) of hydrolyzing all ß-lactams except
aztreonam, and the Ambler class D (OXA-48-like) carbapenemases,
hydrolyzing carbapenems and broad-spectrum cephalosporins only
weakly (Nordmann et al., 2011, 2012a).
Chromogenic and non-chromogenic screening methods for detect-
ing CPE bacteria have been developed. Among chromogenic media,
CHROMagar KPC (CHROMagar Ltd) is effective for detecting VIM and
KPC carbapenemase producers (Kruse et al., 2013), but poorly detects
OXA-48 producers (Girlich et al., 2013b; Nordmann et al., 2012b).
Brilliance CRE (Oxoid, Thermoﬁsher Scientiﬁc) is reported to more
efﬁciently detect KPC- and MBL-producing Enterobacteriaceae (Girlich
et al., 2013b), and the chromogenic medium chromID CARBA
(bioMérieux) well detects CPE, except OXA-48 producers (Girlich
et al., 2013a). Detection of OXA-48-like producers can be efﬁcient
using the chromID OXA-48 medium (bioMérieux) (Girlich et al.,
2013a). The chromID CARBA SMART (bioMérieux) is a selective chro-
mogenic bi-plate medium that selects OXA-48 and non-OXA-48
carbapenemase producers.
Recently, the SUPERCARBAmediumhas been developed and its per-
formances have been compared to those of the chromID CARBA and
chromID OXA-48 media (Girlich et al., 2013a), and to the Brilliance
CRE and CHROMagar KPC media (Girlich et al., 2013b). Those studies
showed that sensitivity of detection of CPE by SUPERCARBA medium
ismuch higher than those obtainedwith Brilliance CRE and CHROMagar
KPC (96.5% versus 76.3% and 43%, respectively), and the speciﬁcity
(60.7%) is higher than that of the Brillance CRE medium (57.1%), al-
though slightly lower than that of the CHROMagar KPC medium
(67.8%). SUPERCARBA medium is as sensitive as the chromID OXA-48
medium for detection of OXA-48 producers, butwith a lower speciﬁcity,
and as sensitive as the chromID CARBA medium for detection of other
classes of carbapenemase producers (90%). Overall, those results dem-
onstrate that the SUPERCARBA medium may detect KPC, MBL and
OXA-48 producers with high sensitivity. A pitfall of this medium is
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Table 1
Limits of detection of CHROMagar mSuperCARBA and SUPERCARBA media and Rapidec® Carba NP test for 117 carbapenemase- and/or ESBL/AmpC-producing enterobacterial isolates.
Strains β-Lactamase content MIC (mg/L) Lowest detection limit (CFU/mL)b






Susceptible to carbapenems (n = 18)
E. cloacae TH12 VEB-1 1 0.25 0.12 N107 107 −
E. coli REG CTX-M-1 0.12 0.06 0.03 N107 N107 −
E. coliMAI CTX-M-14 0.12 0.03 0.03 N107 N107 −
E. coli CTX-M-14 0.06 ≤0.01 0.03 N107 N107 −
E. coli PAR CTX-M-14 0.25 0.06 0.03 N107 N107 −
E. coli DES CTX-M-15 0.12 0.06 ≤0.01 N107 N107 −
E. coli UHR CTX-M-15 0.12 0.25 0.03 N107 107 −
E. coliMED CTX-M-15 0.5 0.06 0.06 N107 N107 −
E. coli 764 CTX-M-15 0.25 0.06 0.03 N107 106 −
E. coli ABD CTX-M-15 0.12 0.12 0.03 N107 106 −
E. coli CAL CTX-M-15 0.5 0.12 0.06 N107 107 −
E. cloacae CTX-M-15 1 0.25 0.06 N107 107 −
E. coli LAG CTX-M-27 0.12 ≤0.01 0.03 N107 N107 −
E. coli THAI3 VEB-1 0.12 0.01 0.03 N107 N107 −
E. coli LOU ACC-1 0.25 0.03 0.03 N107 N107 −
K. pneumoniaeMOR-1 DHA-2 0.5 1 0.12 107 N107 −
P. mirabilis BEL ACC-1 4 0.03 0.12 N107 N107 −
E. coliMET Chromosome-encoded extended-spectrum cephalosporinase 0.25 0.25 0.03 N107 N107 −
Reduced susceptibility to carbapenems (ESBL/overexpressed AmpC/porin deﬁciency) (n = 13)
K. pneumoniaeMEKd CTX-M-15 + SHV-11 1.5 N32 6 101 101 −
K. pneumoniae FOSd CTX-M-15 + TEM-1 + SHV-11 6 N32 N32 101 102 −
K. pneumoniae BERd TEM-1 + SHV-28 1 4 1 101 102 −
K. pneumoniae ALEd CTX-M-15 + SHV-1 1 N32 4 101 105 −
K. pneumoniae SIM CTX-M-15 + TEM-1 + SHV-1 8 N32 6 101 101 −
K. pneumoniae SHM CTX-M-15 + TEM-1 + SHV-11 3 N32 3 102 101 −
K. pneumoniae COO CTX-M-15 + SHV-28 8 N32 4 101 101 −
K. pneumoniae 648,236 SHV2a 0.25 2 0.38 101 102 −
K. pneumoniae BED CTX-M-15 + TEM-1 + SHV-11 2 N32 8 101 101 −
K. pneumoniae CTX-M-15 + TEM-1 + SHV-11 2 N32 8 101 101 −
K. pneumoniae CTX-M-15 + TEM-1 + SHV-1 0.38 24 1.5 102 101 −
E. coliMARe Overexpressed AmpC 16 N32 2 101 5 × 103 −
E. coli SW CTX-M-15 1 24 4 101 101 −
KPC producers (n = 17)
K. pneumoniae SAG KPC-2c + OXA-9 + TEM-1 N32 N32 N32 101 101 +
K. pneumoniae THO KPC-2 + OXA-9 + TEM-1 N32 N32 N32 101 101 +
K. pneumoniae TIF KPC-2 + OXA-9 + TEM-1 N32 N32 N32 101 101 +
K. pneumoniae LIE KPC-2 + OXA-9 + TEM-1 N32 N32 N32 101 5 × 101 +
K. pneumoniae 588 KPC-2 + OXA-9 + SHV-11 + TEM-1 24 32 16 101 101 +
K. pneumoniae A33504 KPC-2 + CTX-M-2 + SHV-11 + OXA-9 + TEM-1 N32 N32 N32 101 101 +
K. pneumoniae 475 KPC-2 + CTX-M-15 + SHV-11 16 N32 N32 101 101 +
E. coli COL KPC-2 + CTX-M-9 + TEM-1 4 4 2 101 101 +
E. cloacae HPT2 KPC-2 1 1.5 0.75 101 101 +
E. cloacae CFVL KPC-2 + TEM-3 4 2 1 101 101 +
K. pneumoniae SUZ KPC-3 32 N32 32 101 101 +
K. pneumoniae JUL KPC-3 N32 N32 N32 101 101 +
K. pneumoniae ELB KPC-3 N32 N32 N32 101 101 +
K. pneumoniae TER KPC-3 32 N32 N32 102 102 +
K. pneumoniae CHRIS KPC-3 + TEM-1 + SHV-11 + OXA-9 32 N32 32 101 101 +
K. pneumoniae GRE KPC-3 + TEM-1 + SHV-11 + OXA-9 N32 N32 N32 101 101 +
K. pneumoniae BEN KPC-3 + TEM-1 + SHV-11 + OXA-9 32 N32 32 101 102 +
Metallo-ß-lactamases (n = 33)
K. pneumoniae 10MA NDM-1 + CTX-M-15 + TEM-1 + SHV-11 + SHV-28 + OXA-1 + OXA-9 N32 N32 N32 101 101 +
K. pneumoniae IND NDM-1 + CTX-M-15 + TEM-1 + SHV-28 + CMY-6 + OXA-1 + OXA-9 1 8 4 101 101 +
E. coli RIC NDM-1 + TEM-1 + CMY-16 + OXA-1 + OXA-10 1 3 1 101 101 +
E. coli GUE NDM-1 + TEM-1 + OXA-1 3 3 2 101 101 +
E. coli ALL NDM-1 + CTX-M-15 + TEM-1 OXA-1 + OXA-2 4 N32 8 101 101 +
E. coli IR5 NDM-1 + CTX-M-15 + TEM-1 16 N32 16 101 101 +
E. coli FEK NDM-4 + OXA-1 + CTX-M-15 32 N32 N32 101 101 +
E. coli I5 NDM-4 + CMY-6 + CTX-M-15 32 N32 N32 101 101 +
E. coli 405 NDM-5 + TEM-1 + CTX-M-15 32 N32 N32 101 102 +
E. coli GAL NDM-6 + OXA-1 + CTX-M-15 32 N32 N32 101 101 +
E. coli THA NDM-7 N32 N32 N32 101 101 +
E. coli REI NDM-7 32 N32 N32 102 102 +
K. pneumoniae 0404020 VIM-1 + SHV-5 N32 N32 N32 101 101 +
K. pneumoniae 0404024 VIM-1 N32 N32 N32 101 101 +
K. pneumoniae 0511135 VIM-1 + SHV-12 N32 N32 N32 101 101 +
K. pneumoniae 1,008,055 VIM-1 + SHV-5 4 2 2 101 101 +
K. pneumoniae 1,108,007 VIM-1 + SHV-1 N32 4 4 101 101 +
K. pneumoniae 1,108,009 VIM-1 + SHV-12 8 N32 2 102 101 +











that it does not include chromogenic molecules indentifying enterobac-
terial species.
Therefore, the chromogenic screening medium CHROMagar
mSuperCARBA (CHROMagar company)was developed for the detection
and presumed identiﬁcation of carbapenemase-producing Enterobacte-
riaceae. The aim of this study was to compare the performance of the
CHROMagar mSuperCARBA medium with the SUPERCARBA medium
and to analyze the performances of the subsequent use of the RAPIDEC®
Carba NP test for detection of carbapenemase activity.
A total of 117 clinical strains of Enterobacteriaceae were used. They
had been previously characterized at the molecular level for their β-
lactamase content. These strains were isolated from various clinical
samples (blood cultures, urine, etc...) and represented themost frequent
enterobacterial species producing carbapenemases worldwide. This
collection included 18 susceptible-carbapenem isolates, 13 strains
with reduced susceptibility to carbapenems but non-carbapenemase
producers (ESBL, overexpressed AmpC and/or porin deﬁciency), and a
series of 86 carbapenemase producers including 36 OXA-48-type
producers, 17 KPC producers, 12 NDM producers, 13 VIM producers,
and 8 IMP producers. Minimal inhibitory concentrations (MICs) of
imipenem, ertapenem and meropenem were determined by Etest and
MIC values were interpreted according to the 2014 Clinical and Labora-
tory Standard Institute (CLSI) guidelines (Clinical and Laboratory
Standards Institute, 2014).
Table 1 (continued)
Strains β-Lactamase content MIC (mg/L) Lowest detection limit (CFU/mL)b






K. pneumoniae 1,108,016 VIM-1 + SHV-5 8 N32 2 102 101 +
E. coli 0404018 VIM-1 + CMY-13 3 1.5 1 101 5 × 101 +
E. cloacae 1,008,029 VIM-1 + CTX-M-3 N32 N32 N32 101 2 × 101 +
E. cloacae 1,008,073 VIM-1 4 N32 2 101 2 × 101 +
S. marcescens 1,008,091 VIM-1 + CTX-M-15 N32 N32 N32 101 101 +
E. coli KOW7 VIM-4 16 16 8 101 101 +
K. pneumoniae 0709127 IMP-1 + TEM-1 0.5 4 1 101 101 +
K. pneumoniae 0709124 IMP-1 + TEM-15 8 3 2 101 101 +
E. coli 1,108,013 IMP-1 + TEM-1 0.5 4 1 101 101 +
E. cloacae 1,008,187 IMP-1 8 N32 4 101 101 +
S. marcescens 1,008,175 IMP-1 N32 N32 N32 101 101 +
K. pneumoniae TWA IMP-8 1 1 0.5 101 101 +
E. cloacae TWA IMP-8 1.5 1 1 101 101 +
S. marcescens IBM19 IMP-11 2 8 4 102 101 +
Carbapenemase of the OXA-48-type (n = 36)
K. pneumoniae RAM OXA-48 1 4 1 101 101 +
K. pneumoniae LIB OXA-48 16 16 16 101 101 +
K. pneumoniae TIK OXA-48 0.75 2 0.38 101 101 +
Enterobacter spp. TUR9 OXA-48 0.38 3 0.38 101 101 +
E. cloacae TUR10 OXA-48 0.38 4 0.38 101 101 +
K. pneumoniae T12 OXA-48 1.5 4 0.75 101 101 +
K. pneumoniae OM14 OXA-48 + TEM1 0.5 1 0.38 101 101 +
K. pneumoniae BOU OXA-48 + CTX-M-15 0.38 0.5 0.25 102 101 +
K. pneumoniae EGY OXA-48 + CTX-M-15 2 3 2 101 101 +
K. pneumoniae ROU OXA-48 + CTX-M-15 0.5 1.5 0.25 101 101 +
K. pneumoniae BAJ OXA-48 + CTX-M-15 + SHV-28 + TEM-1 0.5 1.5 0.38 101 101 +
K. pneumoniae BEN OXA-48 + CTX-M-15 + SHV-28 + TEM-1 0.38 1 0.25 101 101 +
K. pneumoniae DUW OXA-48 + CTX-M-15 + SHV-28 + TEM-1 32 32 32 101 101 +
K. pneumoniae SIC OXA-48 + CTX-M-15 + SHV28 0.25 1 0.25 101 101 +
K. pneumoniae AMS OXA-48 + CTX-M-15 + TEM-1 + OXA-1 0.5 2 0.38 101 101 +
K. pneumoniae ELK OXA-48 + CTX-M-15 + TEM-1 + SHV-11 0.5 3 0.38 101 101 +
K. pneumoniae VSG OXA-48 + CTX-M-15 + OXA-1 + TEM-1 0.75 3 0.75 101 101 +
K. pneumoniae HPA OXA-48 + CTX-M-15 + OXA-1 + TEM-1 1.5 N32 12 101 101 +
K. pneumoniae OM11 OXA-48 + CTX-M-14 + TEM-1 0.5 0.75 0.25 101 101 +
E. coli BOU OXA-48 + CTX-M-15 0.5 0.75 0.12 101 101 +
E. coli BON OXA-48 + CTX-M-24 + TEM-1 0.38 0.5 0.19 101 102 +
E. cloacae TUR OXA-48 + SHV-5 0.5 0.5 0.5 101 101 +
K. pneumoniae Af18 OXA-181 N32 N32 N32 101 101 +
K. pneumoniae Af54 OXA 181 N32 N32 32 101 101 +
K. pneumoniae Af56 OXA-181 N32 N32 N32 101 101 +
K. pneumoniae Af39 OXA-181 1 N32 12 101 101 +
K. pneumoniae Af53 OXA-181 3 N32 4 101 101 +
K. pneumoniae DEL OXA-181 + SHV11 + CTX-M-15 + TEM-1 N32 N32 N32 101 101 +
K. pneumoniae HOL OXA-181 + CTX-M-15 8 N32 32 101 101 −
E. coli LIEU OXA-181 + CTX-M-15 1 1 0.25 102 102 +
K. pneumoniae 479 OXA-204 + CMY-4 8 16 8 101 101 +
E. coli GRA OXA-204 + CMY-2 + CTX-M-15 + OXA-1 2 1 0.25 102 101 +
E. coli DUP OXA-204 + CMY-4 + CTX-M-15 + OXA-1 2 1 0.25 101 102 +
E. coli BAR OXA-204 + CMY-4 + CTX-M-15 2 2 0.5 102 102 +
K. pneumoniae DEL OXA-232 + SHV-1 + TEM-1 + CTX-M-15 + OXA-1 8 N32 32 102 102 −
K. pneumoniae RAN OXA-232 + SHV-1 + TEM-1 + CTX-M-15 + OXA-1 + NDM-1 N32 N32 N32 101 101 +
a IPM = Imipenem; ETP = ertapenem; MEM = meropenem.
b Underlined colony-forming unit counts are considered as negative results (cut-off values set at ≥1 × 103 CFU/plate).
c Boldened β-lactamase names correspond to carbapenemase.
d Reduced susceptibility to ertapenem due to porin deﬁciency.











The SUPERCARBA plates were prepared as described previously
(Nordmann et al., 2012b) and the new CHROMagar mSuperCARBA
plates were prepared following themanufacturer's instructions. The in-
oculum of 0.5 McFarland corresponds to approximately 108 CFU/mL,
and 100 μL of serial 10-fold dilutions were plated on the selective
media SUPERCARBANP and CHROMagarmSuperCARBA. Viable bacteria
were counted from growth on Lisogenic Broth (LB) (Sigma) plates after
24 hours. Sensitivity and speciﬁcity were calculated for every medium
and a limit value of 1 × 103 CFU/platewas considered as negative result,
as previously described (Girlich et al., 2013a, b).
CHROMagar mSuperCARBA medium showed 100% sensitivity and
100% speciﬁcity for KPC, NDM, VIM, IMP and more interestingly OXA-
48-type producers were better selected compared to SUPERCARBA me-
dium (Table 1). This is noteworthy considering that the SUPERCARBA
medium has the highest sensitivity for detection of OXA-48 producers
either with low or high inoculums (93–100%, respectively) (Girlich
et al., 2013a, b). Moreover, 100% of sensitivity and speciﬁcity was en-
countered for bacteria with reduced susceptibility. Noticeably, 2 addi-
tional isolates with reduced susceptibility to carbapenems were
selected by the CHROMagar mSuperCARBA medium as compared to
the SUPERCARBA medium. The limit of detection of those strains on
the SUPERCARBA medium was indeed higher than the 103 CFU/plate
cut-off value with SUPERCARBAmedium, but this problem was not ob-
served with the novel CHROMagar mSuperCARBA medium. On the
other hand, chromogenic reactions of this novel medium produced
the expected species identiﬁcation (data not shown).
In addition, we evaluated the incompatibility of using ﬁrst bacteria
grown on CHROMagar mSuperCARBA medium and then the RAPIDEC®
CARBA NP test. A total of 99 strains grown on this chromogenic medium
(10 μL loop of bacterial colonies) were analyzed according to the
manufacturer's instructions. Clear positive results for KPC, NDM, VIM
and IMP producers were observed, while therewas some variable degree
of color change among the OXA-48-like producers (Table 1). Two OXA-
48-like (OXA-181 and OXA-232) producers that were negative for
RAPIDEC® CARBA NP test were negative even when bacteria were
grown in LB plates showing that there was no chromogenic interference.
In conclusion, our results indicate that using ﬁrst the novel chromo-
genic CHROMagar mSuperCARBA medium to select for carbapenem-
resistant isolates and then the RAPIDEC® CARBA NP test offers a valu-
able option for screening carbapenemase producers.
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